Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The company offers human health pharmaceutical for various areas, including oncology, vaccines, hospital acute care, cardiovascular, virology, neuroscience, and diabetes under the Keytruda, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, RotaTeq, Pneumovax 23, Bridion, Dificid, Zerbaxa, Noxafil, Winrevair, Adempas, Verquvo, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. It also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, Bovilis Cryptium, Banamine, Estrumate, Matrix, Resflor, Zuprevo, Revalor, Safe-Guard, M+Pac, Porcilis, Circumvent, Nobilis/Innovax, Paracox and Coccivac, Exzolt, Slice, Imvixa, Clynav, Aquavac/Norvax, Aquaflor, Flexolt brands; Allflex Livestock Intelligence solutions for animal identification, monitoring and traceability; and companion animal products under the Bravecto One-Month, Bravecto Injectable/Quantum, Bravecto Plus, Sentinel Spectrum, Sentinel Flavor Tabs, Optimmune, Nobivac NXT, GilvetMab, Otomax, Mometamax, Mometamax Ultra, Posatex, Caninsulin/Vetsulin, Panacur, Regumate, Prestige, Scalibor/Exspot, Sure Petcare, and Home Again brands. The company has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates; AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types, and Koselugo for multiple indications; licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova; and collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. was founded in 1891 and is headquartered in Rahway, New Jersey.

Merck & Company Inc.

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Merck & Company (MRK) and Alto Neuroscience, Inc. (ANRO). Merck &...

Analysts Conflicted on These Healthcare Names: Merck & Company (MRK) and Alto Neuroscience, Inc. (ANRO)

In a report released yesterday, Hans Engel from Erste Group maintained a Hold rating on Merck & Company. The company’s shares closed yesterday at $...

Erste Group Sticks to Its Hold Rating for Merck & Company (MRK)

Geopolitical tensions in the Middle East and elevated oil prices continue to rattle investors. Given an uncertain backdrop, investors looking for l...

Best ETFs to Invest In, According to AI Analyst

Jefferies analyst maintained a Buy rating on Merck & Company today and set a price target of $138.00. In addition to Jefferies, Merck & Company als...

Merck & Company (MRK) Gets a Buy from Jefferies

In a report released yesterday, Trung Huynh from RBC Capital maintained a Buy rating on Merck & Company, with a price target of $142.00. According ...

RBC Capital Sticks to Its Buy Rating for Merck & Company (MRK)

In a report released yesterday, from Shore Capital reiterated a Hold rating on Marks Electrical Group Plc. The company’s shares closed yesterday at...

Shore Capital Keeps Their Hold Rating on Marks Electrical Group Plc (MRK)

Investors will find the hottest stock market stories for Wednesday in our wrap-up.


Morning News Wrap-Up 3/25/26: Today’s Biggest Stock Market Stories!

U.S.-based Merck & Co. ($MRK) is reportedly nearing a $6 billion all-cash deal to acquire biotech company Terns Pharmaceuticals ($TERN) as part of ...

Merck Chases $6B Terns Pharma Deal Ahead of Keytruda Patent Expiry — TERN and MRK Stocks Rise

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Merck & Company (MRK), Chemed (CHE) and PROCEPT BioR...

Analysts Offer Insights on Healthcare Companies: Merck & Company (MRK), Chemed (CHE) and PROCEPT BioRobotics (PRCT)

The latest update is out from Marker Therapeutics ( ($MRKR) ). Marker Therapeutics reported 2025 results highlighting clinical progress for its lea...

Marker Therapeutics Highlights Strong MT-601 Data and Prepares for Key 2026 Milestones

IHI, IHE, ARKG: Specialty Healthcare ETFs Offer Diversification and Growth to Investors

Merck KGaA received a Hold rating and an €112.00 price target from Bernstein analyst Justin Smith yesterday. The company’s shares closed yesterday ...

Merck KGaA (0O14) Receives a Hold from Bernstein

J.P. Morgan analyst Richard Vosser maintained a Buy rating on Merck KGaA today and set a price target of €150.00. Vosser covers the Healthcare sect...

J.P. Morgan Remains a Buy on Merck KGaA (0O14)

U.S. stocks ended the week lower as war risk in the Gulf and fresh macro data weighed on sentiment. The S&P 500 (SPX) fell 1.6% for the week and cl...

The Week That Was, The Week Ahead: Macro and Markets, Mar. 15

In a report released on March 13, David Evans from Kepler Capital maintained a Buy rating on Merck KGaA, with a price target of €152.00. The compan...

Kepler Capital  Sticks to Its Buy Rating for Merck KGaA (0O14)

In a report released yesterday, Courtney Breen from Bernstein maintained a Hold rating on Merck & Company, with a price target of $100.00. The comp...

Merck & Company (MRK) Gets a Hold from Bernstein

Barclays analyst Brendan Lynch maintained a Buy rating on Newmark Group today and set a price target of $19.00. According to TipRanks, Lynch is an ...

Barclays Reaffirms Their Buy Rating on Newmark Group (NMRK)

Barclays analyst Emily Field maintained a Buy rating on Merck & Company today and set a price target of $140.00. According to TipRanks, Field is a ...

Barclays Keeps Their Buy Rating on Merck & Company (MRK)

Healthcare is diverse sector of the economy. 


IHI, IHE, ARKG: Specialty Healthcare ETFs Offer Portfolio Diversification to Investors

This article spotlights three ETFs with Outperform ratings and significant upsides, as flagged by TipRanks’ AI analysts.


3 Best ETFs to Invest In, According to AI Analyst, 03/10/2026

In a report released today, Trung Huynh from RBC Capital maintained a Buy rating on Merck & Company, with a price target of $142.00. Huynh covers t...

Goldman Sachs analyst James Quigley maintained a Buy rating on Merck KGaA today and set a price target of €153.00. According to TipRanks, Quigley i...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	MRK	$120.87	0.00%	6.39M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	MRK	$120.87	0%	6.39M
3
4
5
6

MRK

MRK

Get Merck & Company Inc. Data in Excel

Get Merck & Company Inc. Data in Excel